Bringing value to life through innovation

Vygon’s name has become synonymous with quality and reliability in the field of pharmaceuticals.

Early 2014, Vygon decided to open a subsidiary in Singapore to strengthen its presence in Asia-Pacific. Since then, the new site has become a base for the company’s local development and to support distribution channel sales in the region. Vygon is expected to continue its strong growth in the region with their accelerate advancement of products driven by the latest trends in the healthcare industry.

With expertise throughout the value chain, from product design to the delivery of training for medical personnel, Vygon provides health care professionals with effective and innovative products tailored to meet their needs and those of their patients, with maximum safety, efficiency and comfort. Vygon products are designed by the group’s engineers. They are manufactured in eight production units compliant with the ISO 9001 standard, ISO 13485 medical standard and ISO 14001 environmental standard.

Revolutionizing delivery of healthcare IT

In April this year, Vygon launched safe-enteral.com, a website dedicated to the therapeutic implications of enteral tubing and connectors. The site provides information for medical staff and raises awareness about the therapeutic benefits and risks associated with the new connection standards for enteral feeding devices. The site has a special focus on premature neonates and newborns; considered to be high-risk populations.

Since September 2015, Vygon has offered a full range of ENFit™ products, for adult and children, including administration sets for enteral feeding pumps, syringes and feeding tubes.However, for some high-risk patient populations, such as premature neonates and newborns, the ENFit™ connector can involve a risk of drug overdose, which was identified by Vygon thanks to its 10 years expertise in accurate safety feeding systems for neonatology.

The company’s key strategic move in the next three years is the roll-out of Vygon Safe enteral feeding in Singapore and Asia Oceania region via its Singapore based operations. By taking greater strides in growing their presence in the region, Vygon will strive to develop innovative ways to reach a broader range of customers and meet the increasing demands of healthcare professionals and patients. Vygon is not only present in the neonatology fields but also offers unique solutions for the haemodynamic monitoring and for oncology or for emergency medicine. Vygon intends to continue to develop its business through innovation, industrial performance and education to contribute up to 20% of the group sales in 2022 in the global region.

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

Asia insurers risk irrelevance as protection gaps widen
An expert said Singapore saves 36% of its income despite having high protection and critical illness gaps.
Insurance
Banks urged to turn pricing into a strategic growth lever
A consultant says data-driven pricing can boost revenue and lower funding costs without sacrificing volume.
AI governance failures threaten banks’ returns
95% of GenAI spend has no outcome as organisations remain in the early stages of adoption.